Abstract
40 kDa peginterferon alfa-2A (PEGASYS®) as a prophylaxis against hepatitis C infection recurrence after liver transplantation (LT): preliminary results of a randomized multicenter trial: Cosme Manzarbeitia, Albert Einstein Medical Center, Philadelphia, PA; Lewis Tepermann, New York University Medical Center, New York, NY; Naga Chalasani, Indiana University Medical Center, Indianapolis, IN; Patricia Sheiner, Mount Sinai Medical Center, New York, NY; Russel
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
